---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001526"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:32:03.979420+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus Q4 net loss $12.3M; soquelitinib atopic dermatitis Ph1 75% EASI75; raises $189M

## Summary
- Net loss for Q4 2025 was $12.3M; R&D expenses $9.9M (up from $6.0M in Q4 2024).
- Cash $56.8M at Dec 31, 2025; $189.4M net from Jan 2026 offering extends runway into Q2 2028.
- Cohort 4 atopic dermatitis: 75% soquelitinib patients achieved EASI 75 vs 20% placebo; 33% IGA 0/1 vs 0%.
- Initiated Phase 2 atopic dermatitis trial in Q1 2026; ~200 patients, four dose arms, 12-week treatment.
- Phase 3 PTCL registrational trial enrolling; soquelitinib granted Fast Track and Orphan Drug Designation.

## SEC filing metadata
- accession: 0001171843-26-001526
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/0001171843-26-001526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/f8k_031226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001526
- JSON: https://secwatch.observer/filing/0001171843-26-001526.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.